Welcome to our dedicated page for ProMIS Neurosciences SEC filings (Ticker: PMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ProMIS Neurosciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ProMIS Neurosciences's regulatory disclosures and financial reporting.
On 21 Jul 2025 ProMIS Neurosciences (PMN) filed an 8-K disclosing two material items.
- ATM program terminated: The Company and BTIG mutually ended the US$25 m at-the-market agreement first signed 5 Jan 2024. Only 75,862 shares were sold for gross proceeds of US$190,274, leaving US$24.8 m unused. No termination penalties apply and no further shares will be issued under this facility.
- Pipeline progress: The FDA granted Fast Track Designation to PMN310, ProMIS’s lead monoclonal antibody for Alzheimer’s disease. A Data & Safety Monitoring Board has authorised escalation to the 10 mg/kg cohort in the ongoing Phase 1b trial, and, as of 21 Jul 2025, no amyloid-related imaging abnormalities (ARIA) have been observed.
The filing contains no financial results, but it removes potential equity dilution from the ATM, while regulatory momentum for PMN310 could shorten the development timeline.